公开(公告)号：US5580559A

公开(公告)日：1996-12-03

申请号：US311848

申请日：1994-09-23

Applicant: Bhanu Rajput ,  Bhabatosh Chaudhuri ,  Fredericus A. M. Asselbergs ,  Bernd Meyhack ,  Jutta Heim ,  Jan van Oostrum ,  Sefik Alkan

Inventor： Bhanu Rajput ,  Bhabatosh Chaudhuri ,  Fredericus A. M. Asselbergs ,  Bernd Meyhack ,  Jutta Heim ,  Jan van Oostrum ,  Sefik Alkan

IPC: C07K14/735 ,  C12N9/72 ,  C12N15/67 ,  C12N15/85 ,  A61K38/49 ,  C12N9/48 ,  C12N9/64

CPC classification number: C12N9/6456 ,  C07K14/70535 ,  C12N15/67 ,  C12N15/85 ,  C07K2319/00 ,  C07K2319/02 ,  C12N2800/108 ,  C12N2830/002 ,  C12N2830/702

Abstract: Novel single-chain hybrid plasminogen activators having an amino acid sequence composed of at least two subsequences corresponding in amino acid identity and number to subsequences of human t-PA and of human u-PA, and mutants thereof in which at least one of the N-glycosylation sites is modified such that glycosylation cannot take place at these sites exhibit valuable pharmacological properties. The hybrid plasminogen activators are produced by recombinant DNA technology.

Abstract translation: 具有由至少两个对应于人t-PA和人u-PA的氨基酸同一性和数量与子序列的亚序列组成的氨基酸序列的新型单链杂交纤维蛋白溶酶原激活物及其突变体，其中至少一个N 糖基化位点被修饰，使得在这些位点不能发生糖基化显示出有价值的药理学性质。 混合型纤溶酶原激活物是通过重组DNA技术产生的。

公开(公告)号：US5242819A

公开(公告)日：1993-09-07

申请号：US808936

申请日：1991-12-13

Applicant: Bhanu Rajput ,  Bhabatosh Chaudhuri ,  Fredericus A. M. Asselbergs ,  Bernd Meyhack ,  Jutta Heim ,  Jan van Oostrum ,  Sefik Alkan

Inventor： Bhanu Rajput ,  Bhabatosh Chaudhuri ,  Fredericus A. M. Asselbergs ,  Bernd Meyhack ,  Jutta Heim ,  Jan van Oostrum ,  Sefik Alkan

IPC: C07K14/735 ,  C12N9/72 ,  C12N15/67 ,  C12N15/85

CPC classification number: C12N9/6456 ,  C07K14/70535 ,  C12N15/67 ,  C12N15/85 ,  C07K2319/00 ,  C07K2319/02 ,  C12N2800/108 ,  C12N2830/002 ,  C12N2830/702

Abstract: Novel single-chain hybrid plasminogen activators having an amino acid sequence composed of at least two subsequences corresponding in amino acid identity and number to subsequences of human t-PA and of human u-PA, and mutants thereof in which at least one of the N-glycosylation sites is modified such that glycosylation cannot take place at these sites exhibit valuable pharmacological properties. The hybrid plasminogen activators are produced by recombinant DNA technology.

Abstract translation: 具有由至少两个对应于人t-PA和人u-PA的氨基酸同一性和数量与子序列的亚序列组成的氨基酸序列的新型单链杂交纤维蛋白溶酶原激活物及其突变体，其中至少一个N 糖基化位点被修饰，使得在这些位点不能发生糖基化显示出有价值的药理学性质。 混合型纤溶酶原激活物是通过重组DNA技术产生的。

公开(公告)号：US20090314639A1

公开(公告)日：2009-12-24

申请号：US12441948

申请日：2007-09-17

Applicant: Michel Daniel Faupel ,  Jan Van Oostrum

Inventor： Michel Daniel Faupel ,  Jan Van Oostrum

IPC: B01D57/02 ,  C07C237/06 ,  C07C233/05

CPC classification number: B01D61/425 ,  B01D67/0093 ,  B01D71/82 ,  C07K1/28 ,  G01N27/44747 ,  G01N27/44795

Abstract: The present invention relates to means and devices for electro-filtration of molecules. The membranes comprise N-acryloyl-tris(hydroxymethyl)aminomethane (NAT) covalently linked to a support. The invention further encompasses compositions comprising an isoelectric buffer covalently bound to N-acryloyl-tris(hydroxymethyl)aminomethane (NAT). In particular, the present invention relates to membranes and devices allowing an isoelectric filtration of molecules in solution.

Abstract translation: 本发明涉及分子电过滤的方法和装置。 膜包含与载体共价连接的N-丙烯酰基 - 三（羟甲基）氨基甲烷（NAT）。 本发明还包括包含与N-丙烯酰基 - 三（羟甲基）氨基甲烷（NAT）共价结合的等电子缓冲剂的组合物。 特别地，本发明涉及允许溶液中分子的等电过滤的膜和装置。

公开(公告)号：US5807824A

公开(公告)日：1998-09-15

申请号：US463224

申请日：1995-06-05

Applicant: Jan van Oostrum ,  William C. Boyar ,  Nicholas G. Galakatos ,  Albert Schmitz ,  Gino Van Heeke

Inventor： Jan van Oostrum ,  William C. Boyar ,  Nicholas G. Galakatos ,  Albert Schmitz ,  Gino Van Heeke

IPC: G01N33/566 ,  A61K38/00 ,  A61K39/395 ,  A61P1/00 ,  A61P1/16 ,  A61P9/08 ,  A61P9/10 ,  A61P11/00 ,  A61P13/02 ,  A61P15/00 ,  A61P17/00 ,  A61P19/06 ,  A61P25/00 ,  A61P25/28 ,  A61P29/00 ,  A61P31/04 ,  A61P37/06 ,  A61P43/00 ,  C07H21/04 ,  C07K14/47 ,  C07K16/18 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/12 ,  C12P21/02 ,  C12P21/08 ,  C12R1/19 ,  A61K38/16

CPC classification number: C07K14/472 ,  C07K16/18 ,  A61K38/00 ,  C07K2319/00

Abstract: Disclosed are polypeptide analogues of human C5a which are C5a receptor antagonists that exhibit substantially no analphylatoxin or agonist activity, and derivatives of the analogues, and dimeric forms of the analogues or derivatives. DNA molecules encoding the polypeptides and methods of making the analogues are also provided. Pharmaceutical formulations containing a C5a analogue, are used therapeutically in the treatment of C5a-mediated diseases and inflammatory conditions in mammals, and prophylactically to prevent or reduce inflammation caused by an event which causes inflammation or aggravates an existing inflammatory condition, respectively. Further disclosed are antibodies specific to the C5a analogues, derivatives thereof, and dimers of the analogues and derivatives which exhibit substantially no cross-reactivity with human C5a. The antibodies are used to detect or quantify circulating C5a analogue or derivative, as well as to modify, e.g., neutralize, the activity of the C5a receptor antagonist in vivo.

Abstract translation: 公开了人C5a的多肽类似物，其是显示基本上没有分泌毒素或激动剂活性的C5a受体拮抗剂，以及类似物的衍生物和类似物或衍生物的二聚体形式。 还提供了编码多肽的DNA分子和制备类似物的方法。 含有C5a类似物的药物制剂在治疗中用于治疗哺乳动物中C5a介导的疾病和炎性病症，并预防性地预防或减少由引起炎症或加重现有炎性病症的事件引起的炎症。 进一步公开的是对C5a类似物，其衍生物和类似物和衍生物的二聚体特异的抗体，其表现出与人C5a基本上没有交叉反应性。 所述抗体用于检测或定量循环C5a类似物或衍生物，以及修饰，例如中和体内C5a受体拮抗剂的活性。

公开(公告)号：US5837499A

公开(公告)日：1998-11-17

申请号：US463377

申请日：1995-06-05

Applicant: Jan van Oostrum ,  William C. Boyar ,  Nicholas G. Galakatos ,  Albert Schmitz ,  Gino Van Heeke

Inventor： Jan van Oostrum ,  William C. Boyar ,  Nicholas G. Galakatos ,  Albert Schmitz ,  Gino Van Heeke

IPC: G01N33/566 ,  A61K38/00 ,  A61K39/395 ,  A61P1/00 ,  A61P1/16 ,  A61P9/08 ,  A61P9/10 ,  A61P11/00 ,  A61P13/02 ,  A61P15/00 ,  A61P17/00 ,  A61P19/06 ,  A61P25/00 ,  A61P25/28 ,  A61P29/00 ,  A61P31/04 ,  A61P37/06 ,  A61P43/00 ,  C07H21/04 ,  C07K14/47 ,  C07K16/18 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/12 ,  C12P21/02 ,  C12P21/08 ,  C12R1/19 ,  C12P21/00 ,  C07K14/435

CPC classification number: C07K14/472 ,  C07K16/18 ,  A61K38/00 ,  C07K2319/00

Abstract: Disclosed are polypeptide analogues of human C5a which are C5a receptor antagonists that exhibit substantially no analphylatoxin or agonist activity, and derivatives of the analogues, and dimeric forms of the analogues or derivatives. DNA molecules encoding the polypeptides and methods of making the analogues are also provided. Pharmaceutical formulations containing a C5a analogue, are used therapeutically in the treatment of C5a-mediated diseases and inflammatory conditions in mammals, and prophylactically to prevent or reduce inflammation caused by an event which causes inflammation or aggravates an existing inflammatory condition, respectively. Further disclosed are antibodies specific to the C5a analogues, derivatives thereof, and dimers of the analogues and derivatives which exhibit substantially no cross-reactivity with human C5a. The antibodies are used to detect or quantify circulating C5a analogue or derivative, as well as to modify, e.g., neutralize, the activity of the C5a receptor antagonist in vivo.

Abstract translation: 公开了人C5a的多肽类似物，其是显示基本上没有分泌毒素或激动剂活性的C5a受体拮抗剂，以及类似物的衍生物和类似物或衍生物的二聚体形式。 还提供了编码多肽的DNA分子和制备类似物的方法。 含有C5a类似物的药物制剂在治疗中用于治疗哺乳动物中C5a介导的疾病和炎性病症，并预防性地预防或减少由引起炎症或加重现有炎性病症的事件引起的炎症。 进一步公开的是对C5a类似物，其衍生物和类似物和衍生物的二聚体特异的抗体，其表现出与人C5a基本上没有交叉反应性。 所述抗体用于检测或定量循环C5a类似物或衍生物，以及修饰，例如中和体内C5a受体拮抗剂的活性。

公开(公告)号：US4071765A

公开(公告)日：1978-01-31

申请号：US639863

申请日：1975-12-11

Applicant: Karel Jan van Oostrum ,  Gerardus Gegorius Petrus VAN Gorkom

Inventor： Karel Jan van Oostrum ,  Gerardus Gegorius Petrus VAN Gorkom

IPC: G01Q20/02 ,  G01Q30/04 ,  H01J37/147 ,  H01J37/244 ,  H01J37/26

CPC classification number: H01J37/1474 ,  H01J37/244 ,  H01J2237/24507 ,  H01J2237/24578

Abstract: In an electron beam apparatus corrections are made for vibrations and field disturbances which cause a lateral beam shift. A detector is arranged in an intermediate image near the beam path and a signal derived therefrom is used for controlling a beam deflection device. When a second beam deflection device is added, the undesired deflection in a scanning electron microscope can be distinguished from the deflection caused by the scanning.

Abstract translation: 在电子束装置中，对导致横向光束偏移的振动和场干扰进行校正。 检测器被布置在光束路径附近的中间图像中，并且从其获得的信号用于控制光束偏转装置。 当添加第二光束偏转装置时，扫描电子显微镜中的不期望的偏转可以与由扫描引起的偏转区分开。